Free Trial

Vir Biotechnology (VIR) News Today

→ Nvidia’s Quiet $1 Trillion Pivot (From Weiss Ratings) (Ad)
Free VIR Stock Alerts
$11.21
-0.02 (-0.18%)
(As of 06/10/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends
June 10 at 11:48 AM | marketbeat.com
Vir Biotechnology (NASDAQ:VIR) Shares Gap Down to $11.23
Vir Biotechnology (NASDAQ:VIR) Shares Gap Down to $11.23
June 9 at 6:42 AM | americanbankingnews.com
Vir Biotechnology (NASDAQ:VIR) Trading Down 8%
June 8 at 5:50 AM | marketbeat.com
Rafferty Asset Management LLC Sells 126,347 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)
Rafferty Asset Management LLC cut its stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 24.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 398,970 shares of the company's stock after selling
June 8 at 1:56 AM | americanbankingnews.com
Morgan Stanley Raises Vir Biotechnology (NASDAQ:VIR) Price Target to $15.00
June 7 at 2:45 PM | marketbeat.com
Vir Biotechnology (NASDAQ:VIR) Shares Down 8%
Vir Biotechnology (NASDAQ:VIR) Trading Down 8%
June 7 at 2:20 AM | americanbankingnews.com
HC Wainwright Reiterates "Buy" Rating for Vir Biotechnology (NASDAQ:VIR)
June 6, 2024 | marketbeat.com
Vir Biotechnology (NASDAQ:VIR) PT Raised to $15.00 at Morgan Stanley
Morgan Stanley boosted their target price on shares of Vir Biotechnology from $12.00 to $15.00 and gave the stock an "equal weight" rating in a research report on Thursday.
June 6, 2024 | americanbankingnews.com
Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $19.00
June 5, 2024 | marketbeat.com
Vir Biotechnology (NASDAQ:VIR) Given New $19.00 Price Target at Needham & Company LLC
Needham & Company LLC boosted their price objective on Vir Biotechnology from $15.00 to $19.00 and gave the stock a "buy" rating in a research note on Wednesday.
June 5, 2024 | marketbeat.com
HC Wainwright Reaffirms "Buy" Rating for Vir Biotechnology (NASDAQ:VIR)
HC Wainwright restated a "buy" rating and issued a $110.00 target price on shares of Vir Biotechnology in a research report on Wednesday.
June 5, 2024 | marketbeat.com
Vir Biotechnology (NASDAQ:VIR) Shares Gap Up to $10.58
Vir Biotechnology (NASDAQ:VIR) Shares Gap Up to $10.58
June 5, 2024 | businesswire.com
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
May 29, 2024 | finance.yahoo.com
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 29, 2024 | businesswire.com
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 29, 2024 | msn.com
Researchers discover vaccine originally created for HIV may also combat cancer
May 29, 2024 | markets.businessinsider.com
Vir Biotechnology Appoints Mark Eisner As EVP And Chief Medical Officer
May 29, 2024 | marketbeat.com
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of "Moderate Buy" from Analysts
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are currently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and four have assigned a buy recomme
May 24, 2024 | markets.businessinsider.com
Buy Rating Affirmed for Vir Biotechnology on Promising CHD and CHB Program Prospects
May 24, 2024 | markets.businessinsider.com
Evaluating Vir Biotechnology: Insights From 5 Financial Analysts
May 24, 2024 | markets.businessinsider.com
Buy Rating Affirmed for Vir Biotechnology on Promising HDV Program and Anticipated Trial Results
May 24, 2024 | marketbeat.com
Panagora Asset Management Inc. Buys New Shares in Vir Biotechnology, Inc. (NASDAQ:VIR)
Panagora Asset Management Inc. purchased a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 94,516 shares of the company's stock, valued at approximately $951,000. Panagora Asset
May 23, 2024 | finance.yahoo.com
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
May 23, 2024 | businesswire.com
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
May 22, 2024 | finance.yahoo.com
Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
May 21, 2024 | marketbeat.com
Vir Biotechnology (NASDAQ:VIR) Stock Price Up 3.4%
Vir Biotechnology (NASDAQ:VIR) Stock Price Up 3.4%
May 21, 2024 | businesswire.com
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
May 13, 2024 | prnewswire.com
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
May 9, 2024 | marketbeat.com
Research Analysts Offer Predictions for Vir Biotechnology, Inc.'s FY2024 Earnings (NASDAQ:VIR)
Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Research analysts at HC Wainwright increased their FY2024 earnings per share estimates for shares of Vir Biotechnology in a research report issued on Tuesday, May 7th. HC Wainwright analyst P. Trucchio now anticipates that the company will post
May 8, 2024 | finance.yahoo.com
Analysts Just Shipped A Stunning Upgrade To Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates
May 7, 2024 | markets.businessinsider.com
Buy Rating Affirmed: Anticipated Breakthroughs in Vir Biotechnology’s Clinical Pipeline
May 7, 2024 | markets.businessinsider.com
Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)
May 7, 2024 | marketbeat.com
Vir Biotechnology (NASDAQ:VIR) Receives Buy Rating from HC Wainwright
HC Wainwright reaffirmed a "buy" rating and set a $110.00 price objective on shares of Vir Biotechnology in a research report on Tuesday.
May 4, 2024 | markets.businessinsider.com
Buy Rating Affirmed for Vir Biotechnology Amid Promising HDV and HBV Treatment Milestones
May 3, 2024 | marketbeat.com
Vir Biotechnology (NASDAQ:VIR) Announces Quarterly Earnings Results
Vir Biotechnology (NASDAQ:VIR - Get Free Report) posted its earnings results on Thursday. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.51. The company had revenue of $56.38 million during the quarter, compared to the consensus estimate of $11.71 million. Vir Biotechnology had a negative net margin of 713.69% and a negative return on equity of 34.92%. The firm's revenue for the quarter was down 10.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.06) earnings per share.
May 3, 2024 | marketbeat.com
Vir Biotechnology's (VIR) "Buy" Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC reissued a "buy" rating and set a $15.00 price objective on shares of Vir Biotechnology in a report on Friday.
May 3, 2024 | marketbeat.com
Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $12.00
JPMorgan Chase & Co. increased their price objective on shares of Vir Biotechnology from $10.00 to $12.00 and gave the stock a "neutral" rating in a research report on Friday.
May 3, 2024 | markets.businessinsider.com
Hold Rating on Vir Biotechnology Amid Financial Concerns and Clinical Trial Uncertainty
May 3, 2024 | finance.yahoo.com
Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Call Transcript
May 3, 2024 | marketbeat.com
Vir Biotechnology (NASDAQ:VIR) Shares Gap Up on Strong Earnings
Vir Biotechnology (NASDAQ:VIR) Shares Gap Up on Better-Than-Expected Earnings
May 3, 2024 | seekingalpha.com
Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders
May 3, 2024 | finance.yahoo.com
Vir Biotechnology Inc (VIR) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
May 3, 2024 | finance.yahoo.com
Q1 2024 Vir Biotechnology Inc Earnings Call
May 2, 2024 | investorplace.com
VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024
May 2, 2024 | msn.com
Vir Biotechnology GAAP EPS of -$0.48 beats by $0.59, revenue of $56.38M beats by $44.67M
May 2, 2024 | businesswire.com
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 1, 2024 | markets.businessinsider.com
Vir Biotechnology earnings preview: what Wall Street is expecting
April 30, 2024 | finance.yahoo.com
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
April 28, 2024 | finance.yahoo.com
With 53% ownership, Vir Biotechnology, Inc. (NASDAQ:VIR) boasts of strong institutional backing
April 26, 2024 | marketbeat.com
Vir Biotechnology (NASDAQ:VIR) Trading 7.6% Higher
Vir Biotechnology (NASDAQ:VIR) Trading Up 7.6%
April 26, 2024 | msn.com
Southern policies help level up investment from East Asia
Get Vir Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.

Shocking $16T Elon Musk Crypto Leak (Ad)

Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.

Click here now to get your copy.

VIR Media Mentions By Week

VIR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VIR
News Sentiment
▼
0.59

0.76
▲
Average
Medical
News Sentiment

VIR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VIR Articles
This Week
▼
15

4
▲
VIR Articles
Average Week

Get Vir Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:VIR) was last updated on 6/10/2024 by MarketBeat.com Staff

From Our Partners
DON’T buy gold until you read this
If you're an American who understands that your money is rotting away as you read this email… Then this is ...
Sasco Gold LLC | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
Hurry! Buy this stock before the Robinhood traders do!
Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...
Traders Agency | Sponsored
AI's Next Magnificent Seven
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
The Oxford Club | Sponsored
Moonshot Coins for the Current Crypto Run
Did you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...
Crypto 101 Media | Sponsored
The Only Energy Play You Should Be Looking At
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...
Wealthpin Pro | Sponsored